US Psychedelic Retreats and FDA Review

Interest in psychedelic drugs for psychological healing and personal growth has led to a rise in psychedelic retreats globally. While many retreats claim safety procedures, researchers in JAMA Network Open highlight potential harms and a lack of industry-wide standards or regulations. In the United States, most psychedelic drugs remain federally illegal, though Donald Trump signed an executive order directing the United States===Food and Drug Administration to accelerate reviews of psychedelics for conditions like PTSD and to lower restrictions on approved substances. However, MDMA was recently rejected as a PTSD treatment due to safety and effectiveness concerns. Experts like John Krystal, Amy McGuire, and Jeffrey Lieberman emphasize the medical risks and the need for careful management, rigorous screening, and professional supervision, especially concerning the discontinuation of other medications like antidepressants.